NEW YORK--(BUSINESS WIRE)--LifeSci Advisors, LLC., a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage on Keryx Biopharmaceuticals (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease.
